- Home
- MMI vs MNKD Comparison
MMI vs MNKD Comparison
Compare MMI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMI
- MNKD
- Stock Information
- Founded
- MMI 1971
- MNKD 1991
- Country
- MMI United States
- MNKD United States
- Employees
- MMI N/A
- MNKD N/A
- Industry
- MMI Real Estate
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- MMI Finance
- MNKD Health Care
- Exchange
- MMI Nasdaq
- MNKD Nasdaq
- Market Cap
- MMI 1.2B
- MNKD 1.4B
- IPO Year
- MMI 2013
- MNKD 2004
- Fundamental
- Price
- MMI $31.08
- MNKD $3.74
- Analyst Decision
- MMI Sell
- MNKD Buy
- Analyst Count
- MMI 1
- MNKD 4
- Target Price
- MMI $30.00
- MNKD $9.75
- AVG Volume (30 Days)
- MMI 171.4K
- MNKD 2.9M
- Earning Date
- MMI 08-06-2025
- MNKD 08-06-2025
- Dividend Yield
- MMI 1.60%
- MNKD N/A
- EPS Growth
- MMI N/A
- MNKD 228.27
- EPS
- MMI N/A
- MNKD 0.10
- Revenue
- MMI $711,994,000.00
- MNKD $297,595,000.00
- Revenue This Year
- MMI $11.69
- MNKD $13.72
- Revenue Next Year
- MMI $24.07
- MNKD $15.21
- P/E Ratio
- MMI N/A
- MNKD $36.25
- Revenue Growth
- MMI 14.79
- MNKD 32.50
- 52 Week Low
- MMI $27.61
- MNKD $3.63
- 52 Week High
- MMI $42.80
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- MMI 55.67
- MNKD 38.22
- Support Level
- MMI $29.40
- MNKD $3.70
- Resistance Level
- MMI $31.58
- MNKD $4.00
- Average True Range (ATR)
- MMI 0.91
- MNKD 0.16
- MACD
- MMI 0.08
- MNKD 0.01
- Stochastic Oscillator
- MMI 77.06
- MNKD 16.47
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.